Evidence map›Paper›PMID 30079487›Full record

ArticleChembiochem : a European journal of chemical biology2018

An Enzyme-Mediated Amplification Strategy Enables Detection of β-Lactamase Activity Directly in Unprocessed Clinical Samples for Phenotypic Detection of β-Lactam Resistance.

Tara R deBoer, Nicole J Tarlton, Reina Yamaji, Sheila Adams-Sapper, Tiffany Z Wu, Santanu Maity, Giri K Vesgesna, Corinne M Sadlowski, Peter DePaola, Lee W Riley and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Aptamer-Based Detection of Ampicillin in Urine Samples.Antibiotics (Basel, Switzerland) · 2020
    Article
  8. Article
  9. Surface-Bound Antibiotic for the Detection of β-Lactamases.ACS applied materials & interfaces · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tara R deBoerDepartment of Bioengineering, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.ORCID 0000-0002-1549-3157
Nicole J TarltonDepartment of Public Health, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Reina YamajiDepartment of Public Health, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Sheila Adams-SapperDepartment of Public Health, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Tiffany Z WuDepartment of Public Health, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Santanu MaityDepartment of Bioengineering, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Giri K VesgesnaDepartment of Bioengineering, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Corinne M SadlowskiDepartment of Bioengineering, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Peter DePaolaDepartment of Bioengineering, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Lee W RileyDepartment of Public Health, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.
Niren MurthyDepartment of Bioengineering, University of California, Berkeley, University Avenue, Berkeley, CA, 94720, USA.ORCID 0000-0002-7815-7337

Funding

Consortium for drug-resistant Gram-negative pathogen detectionR01AI117064 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LEE, LUKE P., MURTHY, NIREN · 2015 to 2019
$5.7M
18F Conjugated Maltodextrins for the Detection of Medical Device InfectionsR01EB020008 · NIBIB · EMORY UNIVERSITY · PI GOODMAN, MARK MYRON, MURTHY, NIREN · 2015 to 2018
$2.4M
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold NanoparticlesR01EB023776 · NIBIB · UNIVERSITY OF CALIFORNIA BERKELEY · PI CONBOY, IRINA M, MURTHY, NIREN · 2017 to 2020
$1.4M
NIAID NIH HHS R01 AI117064NIBIB NIH HHS R01 EB020008NIBIB NIH HHS R01 EB023776
6 · The paper itself

Abstract

Biochemical assays that can identify β-lactamase activity directly from patient samples have the potential to significantly improve the treatment of bacterial infections. However, current β-lactamase probes do not have the sensitivity needed to measure β-lactam resistance directly from patient samples. Here, we report the development of an instrument-free signal amplification technology, DETECT, that connects the activity of two enzymes in series to effectively amplify the activity of β-lactamase 40 000-fold, compared to the standard β-lactamase probe nitrocefin.

Indexed as

Bacterial Infectionsbeta-Lactamasesbeta-Lactam ResistanceCephalosporinsHumansLimit of Detectionbeta-LactamasesCephalosporinsnitrocefinamplificationantimicrobial resistancebeta-lactamasesdiagnosticspoint-of-care diagnosis

Identifiers

PMID30079487
PMCPMC6494105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.